Cosmos Health Adds AI Drug Discovery Expert to Advisory Board
Event summary
- Cosmos Health appointed Dr. Dimitrios Iliopoulos to its Advisory Board on February 24, 2026.
- Dr. Iliopoulos is the Co-Founder and CEO of Athos Therapeutics, focusing on AI-driven drug discovery for autoimmune diseases.
- He has over 130 peer-reviewed publications and has been recognized among the top 2% of scientists worldwide by Stanford University.
- Dr. Iliopoulos has developed innovative AI-enabled strategies that have accelerated drug discovery in oncology and autoimmune diseases.
The big picture
Cosmos Health's appointment of Dr. Iliopoulos underscores its strategic pivot towards AI-driven biotechnology, aligning with broader industry trends of leveraging artificial intelligence for accelerated drug discovery. The move positions the company to compete more effectively in high-value therapeutic areas, though success will hinge on integrating cutting-edge scientific expertise with operational execution. With a diversified healthcare portfolio, Cosmos Health aims to strengthen its R&D initiatives and expand its clinical and commercial impact.
What we're watching
- AI Integration
- How Cosmos Health will leverage Dr. Iliopoulos' expertise to enhance its AI-driven drug discovery capabilities.
- Strategic Expansion
- Whether the appointment signals a broader push into oncology and autoimmune disease therapeutics.
- Execution Risk
- The pace at which Cosmos Health can translate advisory insights into tangible R&D advancements.
Related topics